<DOC>
	<DOCNO>NCT00002392</DOCNO>
	<brief_summary>To ascertain effect thalidomide immune response vaccination polyvalent pneumococcal polysaccharide vaccine tetanus toxoid HIV-infected patient ; particularly , marker immune activation parameter specific , anti-HIV cellular immunity .</brief_summary>
	<brief_title>A Study Thalidomide HIV-Infected Patients Who Are Receiving HAART</brief_title>
	<detailed_description>Patients receive oral thalidomide blind , placebo-controlled study . [ AS PER AMENDMENT 11/25/98 : This double-blind , placebo-controlled trial thalidomide placebo administer 21 day . After first week therapy , patient receive immunization keyhole limpet hemocyanin polyvalent pneumococcal vaccine . Study therapy stop 2 week immunization . Following immunization , detailed evaluation immune response vaccine conduct next 8 week . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . CD4+ cell count 300 500 cells/mm3 . HIV1 RNA &lt; 500 branchedchain DNA assay ( bDNA assay , Chiron ) within 21 day study entry [ AS PER AMENDMENT 11/25/98 : Undetectableplasma HIV titer ( defined FDA ) branchedchain DNA test ] . Established B cell line [ delete AS PER AMENDMENT 11/25/98 ] . Response least one recall antigen vitro assay lymphocyte proliferative response . Life expectancy &gt; 6 month [ delete AS PER AMENDMENT 11/25/98 ] . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Active opportunistic infection HIVrelated malignancy [ HIVrelated malignancy delete AS PER AMENDMENT 11/25/98 ] . Peripheral neuropathy grade 2 high Division AIDS toxicity criterion . Concurrent Medication : Excluded : Other investigational HIVdrugs . Immunomodulatory potentially immunomodulatory drug , glucocorticoid , hematopoietins , interleukin2 , interferon , pentoxifylline . Patients follow prior condition exclude : History serious hypersensitivity tetanus toxoid vaccine component . Prior Medication : Excluded : Previous immunization pneumococcal polysaccharide vaccine [ , AS PER AMENDMENT 11/25/98 , keyhole limpet hemocyanin vaccine ] . Tetanus toxoid booster within 5 year [ delete AS PER AMENDMENT 11/25/98 ] . Other investigational HIVdrugs within 6 week enrollment . Immunomodulatory potentially immunomodulatory drug , glucocorticoid , hematopoietins , interleukin2 , interferon , pentoxifylline within 6 week enrollment . Risk Behavior : Excluded : Active drug alcohol abuse . Required : Effective combination antiretroviral therapy include two nucleoside analog agent ( ZDV , 3TC , ddI , ddC , d4T ) nelfinavir indinavir , least one month prior study entry . [ AS PER AMENDMENT 11/25/98 : On stable , effective , highlyactive antiretroviral therapy combination FDAapproved antiHIV drug least 3 month prior entry . ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>Lymphocyte Transformation</keyword>
	<keyword>Immunity , Cellular</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Immunologic Memory</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Tetanus Toxoid</keyword>
	<keyword>Pneumococcal Vaccines</keyword>
</DOC>